OPT Opthea Limited - ADR
210
$3.62
$0.18
(4.74%)
| Watchers | 210 |
| 52-Wk Low | $1.60 |
| 52-Wk High | $4.40 |
| Market Cap | $299.92M |
| Volume | 105,569.00 |
| 52-Wk High | $4.40 |
| 52-Wk Low | $1.60 |
Opthea to Participate in the 23 Annual Needham Virtual Healthcare ConferenceGlobe Newswire • about 1 month ago
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT Opthea , the Company ), a clinical-stage biopharmaceutical company developing novel...
Share to Feed
Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee ChairMELBOURNE, Australia and PRINCETON, N.J., April 03...
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; Opthea ), a clinical-stage biopharmaceutical company developing novel therapies to...
Opthea Limited (NASDAQ:OPT Get Free Report) was the target of a large drop in short interest in the month of February. As of February 29th, there was short interest totalling 124,100 shares...
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; Opthea ), a clinical-stage biopharmaceutical company developing novel therapies to treat highly...
Opthea (NASDAQ:OPT Get Free Report) and Amgen (NASDAQ:AMGN Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on...
Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointments of Dr...
Surrozen (NASDAQ:SRZN Get Free Report) and Opthea (NASDAQ:OPT Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two...
Global retina expert joins to support sozinibercept development and launch preparationMELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, Opthea ), a...
COAST trial is evaluating the superiority of sozinibercept combined with EYLEA (aflibercept) over EYLEA alone in wet AMD Enrollment of second pivotal trial (ShORe) to complete in calendar Q2 2024...